By what percentage does Timolol typically reduce IOP on average?

Timolol is a non-selective beta-adrenergic antagonist commonly used as a first-line treatment for elevated intraocular pressure (IOP) in patients with glaucoma. The typical reduction in IOP that Timolol achieves is approximately 25%. This percentage reflects the average efficacy of the medication in clinical practice and is consistent with various studies examining its impact on IOP.

Timolol works by decreasing aqueous humor production in the ciliary body, leading to lower pressure in the eye. It’s important for clinicians to have a clear expectation of the IOP reduction provided by Timolol, which helps in managing patient treatment plans effectively. Additionally, achieving a reduction of around 25% can have a significant impact on controlling glaucoma progression and reducing the risk of vision loss. Understanding this specific percentage also aids in the evaluation of how well a patient is responding to treatment and whether adjustments or additional therapies might be necessary.